BGB-45035

Phase 2Small molecule

BeiGene

BGB-45035 is one of 34 small molecule programs targeting Rheumatoid Arthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

Autoimmune DiseasesCompleted

Rheumatoid ArthritisPhase 2

Active, not recruiting

Autoimmune DiseasesPhase 1

Completed

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Actemra

Rituxan

61 3

Simponi

Johnson & Johnson

Preclinical

19 4

Enbrel

IImmunex

Preclinical

64 5

Remicade

OOrganon and Co

Preclinical

43 6

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 7

Actos

Takeda

Preclinical

2 8

Celexa

AbbVie

Preclinical

1 9

Cataflam

Novartis

Preclinical

—10

Velcade

SShilpa Grover, MD, MPH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Rheumatoid Arthritis

NCT07100938

Clinical

Trials by Indication[1]

Rheumatoid Arthritis1 trial

A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis

Recruiting· BeiGene logo

BeiGene·Phase 2·NCT07100938·90 enrolled

Autoimmune Diseases1 trial

Phase 1a/1b Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and Its Safety and Tolerability in Patients With Autoimmune Dermatological Diseases

Completed· BeiGene logo

BeiGene·Phase 1·NCT06342713·203 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BGB-45035. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BGB-45035 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BGB-45035. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeiGene company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BeiGene

BGB-45035

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Rheumatoid Arthritis1 trial

Autoimmune Diseases1 trial

References

Drug Info

Quick Facts

Related News